CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
OncoImmunity is developing MEDIVAC, a software tool for designing personalized cancer vaccines based on neoantigens. This technology aims to improve the accuracy and efficiency of vaccine development, potentially leading to safer and more effective cancer treatments.
Cancer remains a leading cause of disease and death worldwide.
An estimated 14m new cancer cases were diagnosed in 2012 and 22m are predicted by 2023.
Immunotherapy and particularly personalized neoantigen-based vaccines represent an exciting new weapon in the war against cancer, as they are specific to the tumor and potentially safer and more effective than other types of treatment.
However, the design of neoantigen-based cancer vaccines is currently hampered by an inability to reliably select…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
